AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16034820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (intravenous glucose with amino acids)
Number of subjects: 16
Study 16034820 — intervention group
Group type: COMPARATOR
Intervention: Glucose only (intravenous glucose without amino acids)
Number of subjects: 16
Study 12167548 — intervention group
Group type: EXPERIMENTAL
Intervention: Precipitated withdrawal using naloxone under anaesthetic
Number of subjects: 51
Study 12167548 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient withdrawal treatment using clonidine plus symptomatic medication
Number of subjects: 51
Study 12167548 — intervention group
Group type: EXPERIMENTAL
Intervention: Precipitated withdrawal group
Number of subjects: 51
Study 12167548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 12167548 — intervention group
Group type: EXPERIMENTAL
Intervention: Precipitated withdrawal under anesthesia
Number of subjects: 51
Study 10361531 — intervention group
Group type: EXPERIMENTAL
Intervention: Average American diet (37% energy from fat, 17% saturated fat)
Number of subjects: 20
Study 10361531 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 1 diet (30% energy from fat, 10% saturated fat)
Number of subjects: 20
Study 10361531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated-fat diet (26% energy from fat, 6% saturated fat)
Number of subjects: 20
Study 10361531 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study 7555620 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 600 mg/day
Number of subjects: 40
Study 7555620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2209499 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 l Golytely preparation
Number of subjects: 50
Study 2209499 — intervention group
Group type: COMPARATOR
Intervention: 3 l Golytely preparation
Number of subjects: 50
Study 2209499 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 l Golytely preparation (post-study routine)
Number of subjects: 50
Study 7232842 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and chemotherapy
Number of subjects: 53
Study 7232842 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy, chemotherapy, and MER
Number of subjects: 53
Study 31661974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (N-acetylcysteine and mitochondrial agents)
Number of subjects: 133
Study 31661974 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 133
Study 31661974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 31661974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 133
Study 31109838 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Number of subjects: 0
Study 31109838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 0
Study 31109838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both
Number of subjects: 0
Study 28319727 — intervention group
Group type: COMPARATOR
Intervention: No family witness
Number of subjects: 72
Study 28319727 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet family witness
Number of subjects: 72
Study 28319727 — intervention group
Group type: EXPERIMENTAL
Intervention: Distressed family witness
Number of subjects: 72
Study 26386827 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (up to 60 mg/day)
Number of subjects: 175
Study 26386827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 26386827 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 175
Study 23751988 — intervention group
Group type: EXPERIMENTAL
Intervention: Hem-o-lok ligation system
Number of subjects: 53
Study 23751988 — intervention group
Group type: COMPARATOR
Intervention: Endoloop ligature
Number of subjects: 53
Study 21868284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative MRI-guided surgery
Number of subjects: 58
Study 21868284 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgery (control group)
Number of subjects: 58
Study 19454219 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized DNA random fragmentation model and quantitative PCR experiments using two different target sizes.
Number of subjects: 0
Study 17904975 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective fetoscopic laser photocoagulation (SFLP)
Number of subjects: 40
Study 17904975 — intervention group
Group type: COMPARATOR
Intervention: Serial amnioreduction (AR)
Number of subjects: 40
Study 11773987 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR/Trandolapril 180/2mg (VT)
Number of subjects: 93
Study 11773987 — intervention group
Group type: COMPARATOR
Intervention: Enalapril/Hydrochlorothiazide 20/12.5mg (EH)
Number of subjects: 93
Study 12144330 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrichment program (EP) with peer mentor/tutor (PMT) led study groups
Number of subjects: 0
Study 9676035 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF treatment
Number of subjects: 6
Study 9676035 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no G-CSF treatment)
Number of subjects: 6
Study 8063943 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination of at least one random block of renal cortex during nephrectomy for primary renal cell carcinoma
Number of subjects: 0
Study 3177585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenses with well rounded anterior edge profiles
Number of subjects: 4
Study 3177585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rounded posterior edge profile
Number of subjects: 4
Study 3177585 — intervention group
Group type: COMPARATOR
Intervention: Square anterior edge profiles
Number of subjects: 4
Study 30305054 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus bevacizumab (Arm B)
Number of subjects: 51
Study 30305054 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone (Arm A)
Number of subjects: 51
Study 30305054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 51
Study 28709739 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week lifestyle intervention (supervised aerobic exercise/Mediterranean diet)
Number of subjects: 25
Study 28709739 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 age-matched healthy controls)
Number of subjects: 25
Study 28709739 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week lifestyle intervention
Number of subjects: 25
Study 26248323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafast ultrasound imaging in healthy individuals
Number of subjects: 139
Study 26248323 — intervention group
Group type: COMPARATOR
Intervention: Ultrafast ultrasound imaging in patients with vEDS
Number of subjects: 139
Study 23788069 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 350
Study 23788069 — intervention group
Group type: COMPARATOR
Intervention: Patient education about PCA
Number of subjects: 350
Study 23788069 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed PCA design features
Number of subjects: 350
Study 23788069 — intervention group
Group type: COMPARATOR
Intervention: Uncertainty about receiving medicine when pushing the PCA button
Number of subjects: 350
Study 21255195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (20 mg; p.o.)
Number of subjects: 12
Study 21255195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18496261 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime 0.5 microg/kg/min
Number of subjects: 120
Study 18496261 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime 1.0 microg/kg/min
Number of subjects: 120
Study 18496261 — intervention group
Group type: EXPERIMENTAL
Intervention: Istaroxime 1.5 microg/kg/min
Number of subjects: 120
Study 18496261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17147096 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6% blood alcohol level)
Number of subjects: 64
Study 17147096 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic beverage (control)
Number of subjects: 64
Study 12713062 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV-SGC 1200 mg three times daily plus two NRTIs
Number of subjects: 106
Study 12713062 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV-SGC 1600 mg twice daily plus two NRTIs
Number of subjects: 106
Study 12713062 — intervention group
Group type: COMPARATOR
Intervention: SQV-SGC 1200 mg twice daily plus NFV 1250 mg twice daily plus one NRTI
Number of subjects: 106
Study 10738041 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume leukapheresis (LVL) with heparin
Number of subjects: 39
Study 10738041 — intervention group
Group type: COMPARATOR
Intervention: Normal-volume leukapheresis (NVL)
Number of subjects: 39
Study 8805090 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l‐fenfluramine hydrochloride (60 mg orally)
Number of subjects: 69
Study 8805090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 1637895 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis therapy for pneumocystis carinii pneumonia
Number of subjects: 0
Study 1637895 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 3-azido-3-deoxythymidine (AZT)
Number of subjects: 0
Study 1637895 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 3-azido-3-deoxythymidine (AZT)
Number of subjects: 0
Study 6706305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at 2.1 mg X kg‐1 X day‐1
Number of subjects: 197
Study 6706305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at 4.2 mg X kg‐1 X day‐1
Number of subjects: 197
Study 6706305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at 8.4 mg X kg‐1 X day‐1
Number of subjects: 197
Study 6706305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at 16.2 mg X kg‐1 X day‐1
Number of subjects: 197
Study 6706305 — intervention group
Group type: COMPARATOR
Intervention: Chenodeoxycholic acid (CDCA) at 16.9 mg X kg‐1 X day‐1
Number of subjects: 197
Study 6706305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 197
Study 6706305 — intervention group
Group type: COMPARATOR
Intervention: Chenodeoxycholic acid (CDCA)
Number of subjects: 197
Study 30266030 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT (internet-delivered cognitive behavioral therapy)
Number of subjects: 87
Study 30266030 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 87
Study 29460201 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfapump® system
Number of subjects: 60
Study 29460201 — intervention group
Group type: COMPARATOR
Intervention: Large volume paracentesis (LVP)
Number of subjects: 60
Study 26702629 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTP + ACT
Number of subjects: 67
Study 26702629 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 67
Study 26702629 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTP
Number of subjects: 67
Study 25190230 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 0.1% to 1.5% ectopic beats
Number of subjects: 801
Study 25190230 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with >1.5% ectopic beats
Number of subjects: 801
Study 25190230 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥0.1% ectopic beats
Number of subjects: 801
Study 22709747 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation using the CardioFit System (BioControl Medical, Yehud, Israel)
Number of subjects: 650
Study 22709747 — intervention group
Group type: COMPARATOR
Intervention: Standard optimal medical therapy
Number of subjects: 650
Study 20006197 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-administered antibiotics
Number of subjects: 6476
Study 20006197 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPAACT intervention sites
Number of subjects: 6476
Study 20006197 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention sites
Number of subjects: 6476
Study 20006197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2003 to 2004
Number of subjects: 6476
Study 20006197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2004 to 2005
Number of subjects: 6476
Study 20006197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2005 to 2006
Number of subjects: 6476
Study 20006197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2006 to 2007
Number of subjects: 6476
Study 17559725 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy for 6 weeks
Number of subjects: 12
Study 17559725 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive patients)
Number of subjects: 12
Study 15770833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 150 mg/kg/day
Number of subjects: 50
Study 15770833 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 150 mg/kg/day + Amikacin 15 mg/kg/day
Number of subjects: 50
Study 12390444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (0.25 mg/kg)
Number of subjects: 817
Study 12390444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 817
Study 12390444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 817
Study 9706857 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal flap
Number of subjects: 10
Study 9706857 — intervention group
Group type: COMPARATOR
Intervention: Gingivectomy
Number of subjects: 10
Study 8110578 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:200,000 adrenaline at room temperature
Number of subjects: 120
Study 8110578 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:200,000 adrenaline at 38 degrees C
Number of subjects: 120
Study 8110578 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine at room temperature
Number of subjects: 120
Study 8110578 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine at 38 degrees C
Number of subjects: 120
Study 8110578 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed lignocaine
Number of subjects: 120
Study 8110578 — intervention group
Group type: COMPARATOR
Intervention: All groups (including controls)
Number of subjects: 120
Study 2804041 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic technique based on spontaneous respiration
Number of subjects: 0
Study 2804041 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetic technique based on mechanical ventilation
Number of subjects: 0
Study 2804041 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of suxamethonium
Number of subjects: 0
Study 819596 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 49
Study 819596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7405925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 606
Study 7405925 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 606
Study 7405925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin + Ampicillin
Number of subjects: 606
Study 7405925 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-antibiotic therapy
Number of subjects: 606
Study 31502354 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization glides (3 sets of 10 repetitions)
Number of subjects: 30
Study 31502354 — intervention group
Group type: COMPARATOR
Intervention: Sham mobilization (therapist's hand over joint surfaces without gliding force)
Number of subjects: 30
Study 31840969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular cleansing with sterile gauze (group A) 3 times daily for 48 hours
Number of subjects: 63
Study 31840969 — intervention group
Group type: COMPARATOR
Intervention: Ocular cleansing with Iridium® baby gauze containing Echinacea angustifolia (group B) 3 times daily for 48 hours
Number of subjects: 63
Study 30083623 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 64
Study 30083623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study 26931422 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 91
Study 26931422 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training plus Nutritional Supplementation (RTS)
Number of subjects: 91
Study 26931422 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Training (CT)
Number of subjects: 91
Study 24485665 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT plus S-1
Number of subjects: 43
Study 24485665 — intervention group
Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 43
Study 23024190 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg infusion)
Number of subjects: 84
Study 23024190 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg weekly for 12 months)
Number of subjects: 84
Study 23024190 — intervention group
Group type: COMPARATOR
Intervention: Reference group (nonrandomized)
Number of subjects: 84
Study 19602883 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtle cognitive impairment (measured by MMSE)
Number of subjects: 172
Study 19602883 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 172
Study 17558630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically nebulized distilled water (UNDW)
Number of subjects: 36
Study 17558630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically nebulized distilled cold water (UDCW)
Number of subjects: 36
Study 17558630 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 36
Study 17558630 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled cold water (DCW)
Number of subjects: 36
Study 17558630 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 36
Study 15221295 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPECT with 99mTc‐sestamibi injection
Number of subjects: 241
Study 12235452 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of enoxaparin (1.5 mg/kg once daily for 4 days)
Number of subjects: 48
Study 12235452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of enoxaparin (1.5 mg/kg)
Number of subjects: 48
Study 12235452 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonobese volunteers)
Number of subjects: 48
Study 9602765 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose radiotherapy of 5 Gy at the operation field preoperatively
Number of subjects: 57
Study 9602765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 7747098 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced potency inactivated poliovirus vaccine (EIPV)
Number of subjects: 0
Study 7747098 — intervention group
Group type: COMPARATOR
Intervention: Oral poliovirus vaccine (OPV)
Number of subjects: 0
Study 2564208 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551
Number of subjects: 10
Study 2564208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2564208 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 813297 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacycline
Number of subjects: 69
Study 813297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31604814 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop acoustic stimulation during a daytime nap
Number of subjects: 31
Study 31604814 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop acoustic stimulation for word pairs
Number of subjects: 31
Study 25850975 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 0
Study 25850975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 0
Study 25850975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 23445566 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention with vocal training exercises and vocal hygiene habits (experimental group)
Number of subjects: 70
Study 23445566 — intervention group
Group type: COMPARATOR
Intervention: Guidance on vocal hygiene habits (control group)
Number of subjects: 70
Study 20961474 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Workshop (WW) CD‐ROM + Treatment as Usual (TAU)
Number of subjects: 191
Study 20961474 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 191
Study 19271112 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HBc positive patients
Number of subjects: 100
Study 19271112 — intervention group
Group type: COMPARATOR
Intervention: Anti-HBc negative patients
Number of subjects: 100
Study 19271112 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HBc positive patients with HBV-DNA
Number of subjects: 100
Study 17298711 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat diet (30% energy from fat)
Number of subjects: 89
Study 17298711 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20% energy from fat)
Number of subjects: 89
Study 14745389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine sprayed on the major duodenal papilla
Number of subjects: 326
Study 14745389 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution sprayed on the major duodenal papilla (placebo)
Number of subjects: 326
Study 14745389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 326
Study 14745389 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 326
Study 10714841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric lidocaine 5%
Number of subjects: 70
Study 10714841 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5%
Number of subjects: 70
Study 9014067 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 165
Study 9014067 — intervention group
Group type: COMPARATOR
Intervention: Heparin-dihydroergotamine 0.5 mg + 5,000 IU twice a day
Number of subjects: 165